

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/086,286	03/01/2002		Robert D. Torgerson	D0188/7135	3327
7:	590	05/03/2006		EXAMINER	
Elizabeth R. F			BUI, VY Q		
Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue				ART UNIT	PAPER NUMBER
Boston, MA (	Boston, MA 02210			3734	
				DATE MAILED: 05/03/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

		SYP
	Application No.	Applicant(s)
	10/086,286	TORGERSON ET AL.
Office Action Summary	Examiner	Art Unit
	Vy Q. Bui	3734
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
Status		
<ul> <li>1) ⊠ Responsive to communication(s) filed on <u>09 Fe</u></li> <li>2a) ☐ This action is FINAL. 2b) ⊠ This</li> <li>3) ☐ Since this application is in condition for allowant closed in accordance with the practice under E</li> </ul>	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-3,5-10 and 12-14 is/are pending in t 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-3,5-10 and 12-14 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.	
Application Papers		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the original transfer of the contraction of the original transfer original transfer original transfer or the original transfer original transfer original transfer original transfer original transf	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents</li> <li>2. Certified copies of the priority documents</li> <li>3. Copies of the certified copies of the prior application from the International Bureau</li> <li>* See the attached detailed Office action for a list of</li> </ul>	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)  Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

## **DETAILED ACTION**

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 1. Claims 1-3, 5-10, 12-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over CRUZ, Jr-(4,148,664) in view of MECHANIC (5,332,475).

As to claims 1-3, 6-10 and 13-14, Cruz-'664 (col. 4, lines 50-62; col. 6, lines 26-34; Table 1) discloses a fibrous collagen hemostatic product having a bulk density in a range of 1.5-3.7 lbs/ft³ required for a hemostatic product, and a neutral (pH=7) or acidic (pH<7) or alkaline (pH>7) treatment solution for an un-denatured collagen. Cruz-'664 (col. 6, lines 26-340 also discloses avoiding denaturalization of the collagen. Cruz-'664 does not disclose explicitly using water as a treatment as a treatment solution for suspending collagent fibrils as recited in the claim. However, Mechanic-'475 (col. 2, lines 42-68; col. 3, II. 1-2; col. 4, II. 19-53) discloses using collagen fibrils or finely ground bovine skin collagen in a cross-linking process not subjected to an acid dissolution to make collagen fiber/fabric/matrix to be used inside a human being as an implant. Inherently, the product to be used inside a human body must have been sterilized. Specially, MECHANIC (col. 4, lines 54-64; claim 2, lines 1-8) discloses proteinaceous material/collagen fibril(s) being suspended in an aqueous media such as water (having a pH of from about 6.8 to 8.6) to avoid denaturalization of the collagen. Mechanic-'475 explicitly

teaches avoiding denaturalization of collagen fibrils (col. 4, lines 19-50) by suspending collagen fibrils in water (col. 4, lines 50-64). It would have been obvious to one of ordinary skill in the art at the time of the invention to use water as a treatment solution for a hemostatic product as disclosed by Cruz-'664 in view of Mechanic-'475, as using water would minimize denaturalization of the collagen fibrils.

As to claims 5 and 12, Cruz-'664 and Mechanic-'475 disclose a hemostatic collagen product having substantially all limitations in the claims except for a hemostatic agent. It is well known to incorporate a hemostatic agent to a collagen product such as a fabric/matrix/pad to enhance hemostatic effect. It would have been obvious to one of ordinary skill in the art to incorporate a hemostatic agent to MECHANIC collagen product so as to enhance the hemostatic effect of the MECHANIC collagen product.

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vy Q. Bui whose telephone number is 571-272-4692. The examiner can normally be reached on Monday-Tuesday and Thursday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hayes can be reached on 571-272-4959. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

04/27/2006 Vy Q. Bui

Primary Examiner

Art Unit 3734